Related Experiment Video
Updated: Jan 23, 2026
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience
Amro Metwaly Hassan1, Muhammad Abd El-Gawad Shawky1, Ahmed Qasem Mohammed1
1Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Insights
Adding simvastatin to standard triple therapy significantly boosted Helicobacter pylori eradication rates. This finding offers a promising new approach for treating this widespread bacterial infection.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Pharmacology
Background:
- Helicobacter pylori infection is a prevalent global health issue causing gastritis and potentially gastric cancer.
- Increasing antibiotic resistance in H. pylori complicates treatment strategies worldwide.
- Statins, like simvastatin, are explored for potential synergistic effects with antibiotics.
Purpose of the Study:
- To evaluate the efficacy of simvastatin as an adjunct to standard triple therapy for H. pylori eradication.
- To assess if simvastatin improves treatment outcomes in H. pylori-infected patients.
Main Methods:
- A randomized study involving 100 H. pylori-positive patients diagnosed via stool antigen testing.
- Group 1 (N=50) received standard triple therapy (clarithromycin, amoxicillin, omeprazole).
- Group 2 (N=50) received standard triple therapy plus simvastatin (20 mg bid) for 14 days.
Main Results:
- H. pylori eradication was achieved in 82% (41/50) of patients in the simvastatin group.
- Eradication was achieved in 62% (31/50) of patients in the standard therapy group.
- The difference in eradication rates was statistically significant (P<0.022).
Conclusions:
- Simvastatin significantly enhances the eradication rate of H. pylori when added to standard triple therapy.
- This suggests simvastatin is a valuable adjuvant treatment for H. pylori infections.
- The findings address the challenge of increasing H. pylori resistance to conventional therapies.
Abstract:
Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with H. pylori. Methods: This study was conducted on 100 patients diagnosed with H. pylori by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of H. pylori was assessed by a stool antigen test 4 weeks after therapy. Results: Eradication of H. pylori infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (P<0.022). Conclusion: Simvastatin significantly improves the H. pylori eradication rate.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:12Arteries of the Upper Limbs
02:53Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
01:17Veins of Upper Limbs
The deep venous system is primarily composed of the ulnar and radial veins. The ulnar vein, which drains the fingers through the superficial palmar venous arches, and the radial vein, which serves the palms via the deep palmar...
01:07Speciation Rates
01:18Related Rates